Regeneron Pharmaceuticals (REGN)
683.08
0.00 (0.00%)
Regeneron Pharmaceuticals is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines for serious medical conditions
The company is renowned for its cutting-edge research in areas such as genetics, biochemistry, and biology, which has led to the development of a range of therapies for diseases including cancer, eye disorders, and inflammatory conditions. Regeneron's commitment to scientific advancement and collaboration propels its pipeline of novel treatments, aimed at improving patient outcomes and addressing unmet medical needs on a global scale.
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Regeneron To Contact Him Directly To Discuss Their Options
By Faruqi & Faruqi LLP · Via GlobeNewswire · January 29, 2025
REGENERON ALERT: Bragar Eagel & Squire, P.C. is Investigating Regeneron Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc. (NASDAQREGN) on behalf of long-term stockholders following a class action complaint that was filed against Regeneron on January 7, 2025 with a Class Period from November 2, 2023 to October 30, 2024. Our investigation concerns whether the board of directors of Regeneron have breached their fiduciary duties to the company.
By Bragar Eagel & Squire · Via GlobeNewswire · January 28, 2025
America’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at Prestigious Regeneron Science Talent Search
The Regeneron Science Talent Search Celebrates and Rewards Today’s Most Talented Young Minds Driving Innovation and Progress through Scientific Exploration
By Regeneron Pharmaceuticals, Inc. · Via GlobeNewswire · January 23, 2025
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Regeneron To Contact Him Directly To Discuss Their Options
By Faruqi & Faruqi LLP · Via GlobeNewswire · January 22, 2025
REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQREGN) and certain of its officers.
By Bronstein, Gewirtz & Grossman, LLC · Via Business Wire · January 21, 2025
INVESTOR REMINDER: Berger Montague Notifies Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Investors of a Class Action Lawsuit and Deadline
PHILADELPHIA, Jan. 21, 2025 (GLOBE NEWSWIRE) -- A securities class action lawsuit has been filed against REGENERON PHARMACEUTICALS, INC. (“Regeneron” or the “Company”) (NASDAQREGN). The lawsuit has been filed on behalf of purchasers of Regeneron securities between November 2, 2023 and October 30, 2024, inclusive (the “Class Period”).
By Berger Montague · Via GlobeNewswire · January 21, 2025
ROSEN, A RANKED AND LEADING FIRM, Encourages Regeneron Pharmaceuticals, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – REGN
NEW YORK, Jan. 19, 2025 (GLOBE NEWSWIRE) --
By The Rosen Law Firm PA · Via GlobeNewswire · January 19, 2025
Robbins LLP Urges REGN Stockholders with Large Losses to Contact the Firm for Information About the Class Action Against Regeneron Pharmaceuticals, Inc
SAN DIEGO, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (NASDAQREGN) securities between November 2, 2023 and October 30, 2024. Regeneron is a biotechnology company that designs products for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, among others.
By Robbins LLP · Via GlobeNewswire · January 17, 2025
NASDAQ: REGN INVESTOR ALERT: Berger Montague Advises Regeneron Pharmaceuticals (NASDAQ: REGN) Investors of a March 10, 2025 Deadline
PHILADELPHIA, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQREGN) on behalf of purchasers of Regeneron securities between November 2, 2023 through October 30, 2024, inclusive (the “Class Period”).
By Berger Montague · Via GlobeNewswire · January 17, 2025
Rosen Law Firm Urges Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Stockholders to Contact the Firm for Information About Their Rights
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Regeneron Pharmaceuticals, Inc. (NASDAQREGN) between November 2, 2023 and October 30, 2024. Regeneron describes itself as a “biotechnology company that designs products for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, among others.”
By The Rosen Law Firm, P.A. · Via Business Wire · January 14, 2025
Deadline Approaching: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged to Contact Law Offices of Howard G. Smith
Law Offices of Howard G. Smith reminds investors of the upcoming March 10, 2025 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQREGN) securities between November 2, 2023 and October 30, 2024, inclusive (the “Class Period”).
By Law Offices of Howard G. Smith · Via Business Wire · January 14, 2025
REGN Shareholder Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors Class Action Against Regeneron Pharmaceuticals, Inc.
SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) --
By Robbins LLP · Via GlobeNewswire · January 13, 2025
REGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQREGN) and certain of its officers.
By Bronstein, Gewirtz & Grossman, LLC · Via Business Wire · January 13, 2025
Deadline Alert: Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Urged to Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit
Glancy Prongay & Murray LLP reminds investors of the upcoming March 10, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQREGN) securities between November 2, 2023 and October 30, 2024, inclusive (the “Class Period”). Regeneron investors have until March 10, 2025 to file a lead plaintiff motion.
By Glancy Prongay & Murray LLP · Via Business Wire · January 13, 2025
Regeneron Provides Business Updates and Highlights from Broad Clinical Pipeline at the 43rd Annual J.P. Morgan Healthcare Conference
Dupixent® is now used to treat over a million patients globally, with continued growth and expansion in multiple indications for diseases in which type 2 inflammation plays a role
By Regeneron Pharmaceuticals, Inc. · Via GlobeNewswire · January 13, 2025
Adjuvant Libtayo® (cemiplimab) Significantly Improves Disease-Free Survival (DFS) After Surgery in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) in Phase 3 Trial
Primary endpoint of DFS met at first prespecified interim analysis, showing a 68% reduction in the risk of disease recurrence or death in patients with high-risk CSCC after surgery compared to placebo
By Regeneron Pharmaceuticals, Inc. · Via GlobeNewswire · January 13, 2025
Regeneron Collaborates with Truveta and Leading American Health Systems to Massively Extend its DNA Sequence-Linked Healthcare Database to Further Advance Scientific Innovation and Healthcare Delivery
The Truveta collaboration will extend Regeneron Genetics Center’s® (RGCTM) world-leading DNA sequence-linked healthcare database (now including almost three million de-identified patient volunteers) through genetic sequencing of up to ten million additional patient volunteers, all with linked electronic health records, creating the Truveta Genome Project
By Regeneron Pharmaceuticals, Inc. · Via GlobeNewswire · January 13, 2025
REGN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQREGN) securities between November 2, 2023 and October 30, 2024, both dates inclusive (the “Class Period”), have until March 10, 2025 to seek appointment as lead plaintiff of the Regeneron class action lawsuit. Captioned Radtke v. Regeneron Pharmaceuticals, Inc., No. 25-cv-00145 (S.D.N.Y.), the Regeneron class action lawsuit charges Regeneron and certain of Regeneron’s top current and former executives with violations of the Securities Exchange Act of 1934.
By Robbins Geller Rudman & Dowd LLP · Via Business Wire · January 13, 2025
REGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Regeneron Pharmaceuticals, Inc. (NASDAQREGN) securities between November 2, 2023 and October 30, 2024, both dates inclusive (the “Class Period”), have until March 10, 2025 to seek appointment as lead plaintiff of the Regeneron class action lawsuit. Captioned Radtke v. Regeneron Pharmaceuticals, Inc., No. 25-cv-00145 (S.D.N.Y.), the Regeneron class action lawsuit charges Regeneron and certain of Regeneron’s top current and former executives with violations of the Securities Exchange Act of 1934.
By Robbins Geller Rudman & Dowd LLP · Via Business Wire · January 10, 2025
INVESTOR ALERT: Shareholder Class Action Lawsuit Filed Against Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN); DiCello Levitt LLP Encourages Investors with Losses to Discuss Their Options with Counsel
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- A class action lawsuit has been filed on behalf of all persons and entities who purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (NASDAQREGN) (“Regeneron” or the “Company”) common stock between November 2, 2023 and October 30, 2024 (the “Class Period”), charging the Company and certain of its current and former senior executives with violations of the federal securities laws (collectively, “Defendants”).
By DiCello Levitt LLP · Via GlobeNewswire · January 10, 2025
Law Offices of Howard G. Smith Encourages Regeneron Pharmaceuticals, Inc. (REGN) Investors To Inquire About Securities Fraud Class Action
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQREGN) securities between November 2, 2023 and October 30, 2024, inclusive (the “Class Period”). Regeneron investors have until March 10, 2025 to file a lead plaintiff motion.
By Law Offices of Howard G. Smith · Via Business Wire · January 10, 2025
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceuticals, Inc. (“Regeneron” or “the Company”) (NASDAQREGN) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
By The Schall Law Firm · Via Business Wire · January 8, 2025
Stockholder Notice: Robbins LLP Informs Stockholders of the Regeneron Pharmaceuticals, Inc. Class Action Lawsuit
SAN DIEGO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Regeneron Pharmaceuticals, Inc. (NASDAQREGN) securities between November 2, 2023 and October 30, 2024. Regeneron is a biotechnology company that designs products for eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, among others.
By Robbins LLP · Via GlobeNewswire · January 8, 2025
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQREGN) and reminds investors of the March 10, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
By Faruqi & Faruqi, LLP · Via Business Wire · January 8, 2025
Law Offices of Frank R. Cruz Encourages Regeneron Pharmaceuticals, Inc. (REGN) Investors To Inquire About Securities Fraud Class Action
The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of investors who purchased Regeneron Pharmaceuticals, Inc. (“Regeneron” or the “Company”) (NASDAQREGN) securities between November 2, 2023 and October 30, 2024, inclusive (the “Class Period”). Regeneron investors have until March 10, 2025 to file a lead plaintiff motion.
By The Law Offices of Frank R. Cruz · Via Business Wire · January 8, 2025